September 2006
Pharma DD: Tracking Discovery & Development;Sep/Oct2006, Vol. 1 Issue 2, p11
Academic Journal
The article offers news briefs on the pharmaceutical industry. Velcade cancer drug of Millennium Pharmaceuticals should not be paid for on the British National Health Service according to the British National Institute of Health and Clinical Excellence. Development of regulatory guidelines for adaptive clinical trials is being planned by the U.S. Food and Drug Administration. A proposal on the negotiation of drug prices for 43 million elderly and disabled U.S. people eligible for Medicare was made by Democrat lawmakers.


Related Articles

  • Pharmaceutical Company Round-up.  // PharmaWatch: Monthly Review;Dec2008, Vol. 7 Issue 12, p3 

    The article offers world news briefs related to pharmaceutical companies. The multiple myeloma drug, Revlimid, of Celgene is said to be too expensive to be provided on Great Britain's National Health Service (NHS). UCB has announced that the U.S. Food and Drug Administration (FDA) has approved...

  • FDA's REMS plan a new test for Rx.  // Chain Drug Review;8/3/2009, Vol. 31 Issue 13, p24 

    The article reports on the Risk Evaluation and Mitigation Strategies (REMS) of the U.S. Food and Drug Administration (FDA), which are guidelines to regulate the dispensing of opioids. It states that community pharmacies should use technology mandated by the FDA to prevent them from losing the...

  • FDA Pilots New Quality Assessment System.  // Pharmaceutical Technology;Aug2005, Vol. 29 Issue 8, p20 

    Reports on the invitation of the U.S. Food and Drug Administration for several pharmaceutical companies to take part in a pilot program designed to develop guidance for a new quality assessment system. Requirements for companies participating in the program; Usefulness of the result in...

  • Process Validation. Levenson, Michele; Chatterjee, Bikash // Pharmaceutical Processing;Jul/Aug2013, Vol. 28 Issue 6, p42 

    The article focuses on the New Process Validation Guidance issued by the U.S. Food and Drug Administration (FDA). Implementing an effective verification and control strategy to ensure process and product performance is important in the new Process Validation Guidance. The new guidance departs...

  • NEW GUIDANCES: Issues July 2009-May 2010.  // Pharmaceutical Technology;2010 Buyer's Guide, p183 

    The article presents several major U.S. Food and Drug Administration and ICH Manufacturing-Related Guidances issued from July 2009 to May 2010. It includes the Residual Solvents in Drug Products Marketed which assists manufacturers in responding the issuance of US Pharmacopeia (USP). Another is...

  • NEWS & POLITICAL REVIEW. Robinson, Roger; Rhen, Rex; Beecham, Linda; Dillner, Luisa; Luwry, Stella; Christie, Byan; Richards, Tessa; Groves, Trish // BMJ: British Medical Journal (International Edition);6/1/91, Vol. 302 Issue 6788, p1293 

    Reports developments related to medicine as of June 1991. Reduction of the workforce of United States Food and Drug Administration; Possibility of selling the private care of the National Health Service of Great Britain; Sale of cheap drugs developed in Russia.

  • In brief.  // BMJ: British Medical Journal (International Edition);06/17/2000, Vol. 320 Issue 7250, p1622 

    Covers medical-related news briefs as of June 17, 2000. Adoption of Great Britain's National Health Services for an early warning system on reporting untoward incidents to a central register; Possibility of the United States Food and Drug Administration to approve the use of mifepristone;...

  • In brief.  // BMJ: British Medical Journal (International Edition);03/20/99, Vol. 318 Issue 7186, p754 

    Presents news briefs on health-related issues from around the world as of March 1999. Campaign started by the National Health Service of Great Britain to save the money lost through prescription charge evasion; Opening of the office of the World Health Organization in Moscow, Russia;...

  • In brief.  // BMJ: British Medical Journal (International Edition);10/19/2002, Vol. 325 Issue 7369, p852 

    Provides news brief in the medical field as of October 19, 2002. Insufficient evidence for depression screening; Mark McClellan named commissioner for the U.S. Food and Drug Administration; Babies in England and Wales issued their National Health Service number at birth.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics